Dr. Regev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
720 Eskenazi Ave
Indianapolis, IN 46202Phone+1 317-880-8329Fax+1 305-243-8470
Education & Training
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1988
Certifications & Licensure
IN State Medical License 2007 - 2025
FL State Medical License 2001 - 2007
Publications & Presentations
PubMed
- 21 citationsConsensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chroni...William R. Treem, Melissa Palmer, I. Lonjon-Domanec, Daniel Seekins, Lara Dimick-Santos
Drug Safety. 2021-02-01 - 58 citationsDoes the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study.Arie Regev, Constanza Guaqueta, Enrique Molina, Andrew Conrad, Vishnu S. Mishra
Journal of Pediatric Gastroenterology and Nutrition. 2006-07-01 - 3 citationsDrug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.Eric B Cohen, Meenal Patwardhan, Ritu Raheja, David H Alpers, Raul J Andrade
Drug Safety. 2024-04-01
Other
- Diagnosis and management of cystic lesions of the liverRegev A, Reddy KR
http://www.uptodate.com/contents/diagnosis-and-management-of-cystic-lesions-of-the-liver
UpToDate, Wolters Kluwer Health - 2013-03-22
Press Mentions
Consensus: Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Patients with Nonalcoholic SteatohepatitisFebruary 13th, 2020
Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisFebruary 14th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
